Stock has completed its Correction phase and found its lowest at 860, much below the 1700 IPO listing.
Stock seems to be forming a new Higher High and Higher Low Pattern since Oct 2023.
Also it can be seen following the Trendline as well.
A Hammer on the weekly close last week, could indicate a strong support forming exactly on the Trendline, which is a good sign for further upward move.
If all goes right, the stock could make it to its next leg up.
Stoploss mentioned is crucial. If broken, the stock could start seeing further lows.
Stock seems to be forming a new Higher High and Higher Low Pattern since Oct 2023.
Also it can be seen following the Trendline as well.
A Hammer on the weekly close last week, could indicate a strong support forming exactly on the Trendline, which is a good sign for further upward move.
If all goes right, the stock could make it to its next leg up.
Stoploss mentioned is crucial. If broken, the stock could start seeing further lows.
הערה
News:Fosun Is Said To Plan Block Deals To Pare 6% Stake In Gland Pharma - Bloomberg News
עסקה פעילה
Trade back at our Entry Zone.הערה
What a Price movement today. Almost did 80% of our Target in just a single candle. הערה
14% Profits done so far. Trade seems to be going exactly as expected.
Could hit targets sooner than expected.
Keep a close eye.
הערה
Positive News: CO RECEIVES TENTATIVE APPROVAL FROM THE USFDA FOR LATANOPROSTENE BUNOD OPHTHALMIC SOLUTION || SOLTUION HAS US SALES OF APPROXIMATELY USD 153 MILLIONהערה
Positive News: Q1 CONSOL NET PROFIT 1.44 BILLION RUPEES; IBES PROFIT EST. 2.09 BILLION RUPEESהערה
We were so close to our Target Level this week. Just short by 40 points. Hopefully, we will achieve entire target soon.העסקה בוטלה באופן ידני
Achieved Max Profits of 17%. Unfortunately, the trend has reversed and going downward. Better to exit. Do not hold further. Congrats to those who where able to book up to 17% Profits.
כתב ויתור
המידע והפרסומים אינם מיועדים להיות, ואינם מהווים, ייעוץ או המלצה פיננסית, השקעתית, מסחרית או מכל סוג אחר המסופקת או מאושרת על ידי TradingView. קרא עוד ב־תנאי השימוש.
כתב ויתור
המידע והפרסומים אינם מיועדים להיות, ואינם מהווים, ייעוץ או המלצה פיננסית, השקעתית, מסחרית או מכל סוג אחר המסופקת או מאושרת על ידי TradingView. קרא עוד ב־תנאי השימוש.